Qiagen Acquires NGS Analysis Software Company Genoox

QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.

The acquisition adds Franklin, Genoox’s flagship cloud-based community platform, to the QIAGEN Digital Insights (QDI) portfolio, strengthening QIAGEN’s leadership in genetic interpretation for clinical genomics applications. Franklin empowers labs to analyze next-generation sequencing (NGS) data – from targeted gene panels to whole exome and genome sequencing (WES/WGS) - and delivers real-time, AI-driven insights to support clinical decision-making. Applications range from diagnosing genetic disorders and informing cancer treatments to supporting family planning decisions.

Image: QIAGEN has enhanced its leading clinical genomics portfolio with the acquisition of Genoox AI-powered software (Photo courtesy of Genoox)

The platform is currently used by more than 4,000 healthcare organizations in over 50 countries and has powered more than 750,000 case interpretations to date. The acquisition also creates a path to integrate QIAGEN’s genomic content into the Franklin platform that powers the company’s leading QCI Interpret and QCI Precision Insights solutions. These future integrations will expand Franklin’s interpretive power, and in turn improving diagnostic yield, turnaround time and scalability for clinical labs.

“The acquisition of Genoox brings together two complementary strengths to better serve clinical testing laboratories,” said Thierry Bernard, CEO of QIAGEN. “Franklin’s AI-powered solution offers exciting opportunities for labs to rapidly identify the most clinically relevant insights and help improve patient outcomes. Combined with QIAGEN’s trusted clinical knowledge and interpretation tools, the addition of Franklin to our portfolio will enable QIAGEN to better address the challenges of our customers who are seeking easy-to-use, rapid and scalable clinical decision-support solutions.”

“Joining QIAGEN marks a major milestone in our mission to make genomic data more accessible and actionable,” added Amir Trabelsi, Co-founder and CEO of Genoox. “Franklin will benefit from QIAGEN’s global reach and scientific leadership as we scale to support more labs and patients around the world. As part of QIAGEN, we can together drive the next wave of precision medicine.”